Intro to lipids & lipoproteins: why there is no ‘bad’ or ‘good’ cholesterol
I recently posted on Twitter about my frustration with the way the press writes about “good” and “bad” cholesterol, and…
The genetics of PCSK9i nonresponders
A recent case study shines light on why some individuals are resistant to PCSK9 inhibitors.
First Case of Human PCSK9 Gene-Editing
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
Cumulative effects of LDL-C reduction in mitigating cardiovascular risk
Atherosclerotic cardiovascular disease (ASCVD) is currently the leading cause of death in the U.S. One of the most effective ways to reduce risk of ASCVD mortality is reduction of apoB particle number, typically estimated by LDL cholesterol (LDL-C) concentrations.
Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
For triglycerides, “normal” may not be “optimal”
How do triglyceride levels relate to cardiovascular risk?
When CAC Tests Are Useful and When They Are Not
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we…
Comment policyComments are welcomed and encouraged on this site, but there are some instances where comments will be edited or deleted as follows: